Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Steroid hormone antagonism affords vascular protection in a mouse model of vascular Ehlers-Danlos syndrome
Emily E. Juzwiak, Caitlin J. Bowen, Rhiannon Edwards, Leda Restrepo, Serena Lee, Cassie A. Parks, Anthony Zeng, Maya M. Black, Oscar E. Reyes Gaido, Emily E. Bramel, Dustin T. Shigaki, Michael A. Beer, Chiara Bellini, Harry C. Dietz, Elena Gallo MacFarlane
Emily E. Juzwiak, Caitlin J. Bowen, Rhiannon Edwards, Leda Restrepo, Serena Lee, Cassie A. Parks, Anthony Zeng, Maya M. Black, Oscar E. Reyes Gaido, Emily E. Bramel, Dustin T. Shigaki, Michael A. Beer, Chiara Bellini, Harry C. Dietz, Elena Gallo MacFarlane
View: Text | PDF
Research Article Cell biology Vascular biology

Steroid hormone antagonism affords vascular protection in a mouse model of vascular Ehlers-Danlos syndrome

  • Text
  • PDF
Abstract

Aortic dissection or rupture is a leading cause of mortality in vascular Ehlers-Danlos syndrome (VEDS), a disorder caused by mutations in the COL3A1 gene. Col3a1G938D/+ mice recapitulate features of VEDS, including high risk of aortic rupture. As in people with VEDS, aortic risk in this model accelerates at the onset of puberty, especially in males. We identify developmentally regulated gene programs associated with this vulnerability and that are targeted by treatments that mitigate aortic risk. Both genetic and pharmacological inhibition of the androgen receptor (AR) eliminated survival differences between sexes, while treatment with a dual AR and mineralocorticoid receptor (MR) antagonist provided near-complete and durable protection in both sexes. Pathways targeted by dual AR/MR inhibition, including those related to extracellular matrix (ECM) organization and cell-ECM interactions, largely overlapped with those also modulated by isolated MR antagonism. Selective targeting of MR signaling emerged as an effective therapeutic strategy in both sexes that avoids sexual side effects in males.

Authors

Emily E. Juzwiak, Caitlin J. Bowen, Rhiannon Edwards, Leda Restrepo, Serena Lee, Cassie A. Parks, Anthony Zeng, Maya M. Black, Oscar E. Reyes Gaido, Emily E. Bramel, Dustin T. Shigaki, Michael A. Beer, Chiara Bellini, Harry C. Dietz, Elena Gallo MacFarlane

×

Figure 6

AR/MR antagonism upregulates adaptive transcriptional signature in VSMCs, increases medial collagen and elastin content, and alters the passive mechanical properties of the aorta in VEDS mice.

Options: View larger image (or click on image) Download as PowerPoint
AR/MR antagonism upregulates adaptive transcriptional signature in VSMCs...
(A) Heatmap of transcripts previously associated with adaptive response to mechanical stress in aneurysmal aorta (44). Expression is shown in VSMCs from VEDS versus control aorta, and spironolactone (Spiro)-, finerenone (Fine)-, and bicalutamide (Bical)-treated versus untreated VEDS mice. Red = upregulated; blue = downregulated. (B) Representative aortic sections from descending aorta of untreated control, untreated VEDS, and VEDS males treated with spironolactone, finerenone, or bicalutamide or with genetic Ar inactivation. Images show elastin (Alexa Fluor 633 hydrazide, green) and collagen (tdTomato-CNA35, red). Scale bar: 20 μm. (C) Quantification of medial collagen and elastic fiber content (normalized to the average value for untreated VEDS) in the descending thoracic aorta of male untreated control (n = 7) and VEDS (n = 7) mice, spironolactone- (Spiro-) (n = 6) or finerenone-treated (Fine-treated) (n = 6) treated VEDS mice, VEDS mice following genetic (Arnull/y, n = 4), or pharmacological (Bical, n = 5) androgen receptor inhibition. Each symbol represents an individual replicate; P value refers to 1-way ANOVA with Šídák post hoc test. (D) Passive biomechanical properties of descending thoracic aortas from untreated (n = 7) and spironolactone-treated (n = 10) VEDS mice under physiological pressure loads. Each symbol represents an individual replicate; light shading represents females. P value refers to Mann-Whitney U test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts